New Cancer Drug Improves Survival in Relapsed Small-Cell Lung Cancer Trial
Risvutatug rezetecan demonstrated significant overall survival improvement in a Phase III trial for patients with relapsed small-cell lung cancer. The drug reduced the risk of death by 54% compared to topotecan.
Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly improved overall survival in patients with relapsed small-cell lung cancer. The study found that the drug reduced the risk of death by 54% compared to treatment with topotecan.
The ARTEMIS-008 trial was a randomized, open-label Phase III study that enrolled 442 patients with relapsed or refractory small-cell lung cancer. The trial was conducted across multiple countries, including South Korea. Treatment with risvutatug also led to improved progression-free survival and objective response rates when compared to topotecan.
Small-cell lung cancer (SCLC) is an aggressive form of cancer that typically responds well to chemotherapy initially but often recurs rapidly. Current treatment options for relapsed disease are limited. The promising results of risvutatug may offer a new therapeutic option for these patients.
The company plans to submit the trial data to regulatory authorities for approval. Adverse events associated with risvutatug were monitored closely throughout the study and were consistent with previously reported data.